Issue of Equity and Total Voting Rights
SkinBioTherapeutics plc has issued 129,736 new ordinary shares due to a share option agreement, with admission expected on January 22, 2026. Following this issuance, the company's total voting rights will increase to 258,779,463 ordinary shares. This new total will serve as the denominator for shareholders calculating their notification obligations under FCA rules.
Select text to share a quote on X · sign in to keep highlights & notes in your SBTX notes
20 January 2026 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the life science business focused on skin health, announces that it has issued, conditional on admission, 129,736 new ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares"), pursuant to the share options agreement entered into by the Company and a previous employee upon IPO.
The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in issue and application has been made for the new Ordinary Shares to be admitted to trading on the AIM Market of the London Stock Exchange ("Admission"). Admission is expected to occur, and dealings in the new Ordinary Shares commence, at 8:00 a.m. on 22 January 2026.
Total Voting Rights
Following Admission, the Company will have 258,779,463 Ordinary Shares in issue. This figure of 258,779,463 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.